{
    "clinical_study": {
        "@rank": "110771", 
        "arm_group": [
            {
                "arm_group_label": "Treatment A", 
                "description": "Controlled release oxycodone test formulation 40 mg"
            }, 
            {
                "arm_group_label": "Treatment B", 
                "description": "Immediate release oxycodone reference drug 20 mg"
            }
        ], 
        "brief_summary": {
            "textblock": "To determine whether the bioavailability of the controlled-release test formulation is at\n      least as high as that for the commercial reference drug."
        }, 
        "brief_title": "A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "Serial sampling of venous blood"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  healthy volunteers, greater than 50 kg, able and willing to sign informed consent\n\n        Exclusion Criteria:\n\n          -  Evidence of significant illness, condition affecting drug absorption, history of\n             sleep apnea, and allergy to opioid drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Healthy adult volunteers"
            }
        }, 
        "enrollment": {
            "#text": "14", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01677065", 
            "org_study_id": "B4531007", 
            "secondary_id": "ALO-02 Bioavailability Study"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment A", 
                "description": "single dose administration of test formulation under fasted conditions", 
                "intervention_name": "Oxycodone controlled-release test formulation", 
                "intervention_type": "Drug", 
                "other_name": "ALO-02"
            }, 
            {
                "arm_group_label": "Treatment B", 
                "description": "single dose administration of reference drug under fasted conditions", 
                "intervention_name": "Immediate-release reference drug", 
                "intervention_type": "Drug", 
                "other_name": "Roxicodone"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Naltrexone", 
                "Oxycodone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Bioavailability", 
            "Oxycodone", 
            "Healthy Volunteers"
        ], 
        "lastchanged_date": "October 22, 2012", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B4531007&StudyName=A%20Randomized%2C%20Two-way%2C%20Crossover%20Study%20to%20Estimate%20the%20Relative%20Bioavailability%20of%20%20a%20Controlled-release%20Formulation%20of%20Oxycodone%20%2840%"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06511"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "An Open-label, Single-dose, Randomized, Two-way Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "pharmacokinetic endpoints - area under the concentration curve (AUC)", 
            "safety_issue": "No", 
            "time_frame": "0-48 hr"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01677065"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Peak concentration (Cmax) and time to peak concentration (Tmax)", 
            "safety_issue": "No", 
            "time_frame": "0-48 hr"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Observational Model: Case-Crossover, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "October 2012"
    }
}